All Episodes
|
52
|
John Marchica

Episode 52: Our Take, June 3, 2019

Jun 3, 2019

Episode Summary

In this week’s episode, John reviews Novartis’ new gene therapy for spinal muscular atrophy, priced at more than $2.1 million. ICER, a nonprofit research institute that evaluates the cost effectiveness of pharmaceuticals, said Novartis’ price is within the upper bound of the organization’s value-based price benchmark range.

Episode Notes

In this week’s episode, John reviews Novartis’ new gene therapy for spinal muscular atrophy, priced at more than $2.1 million. ICER, a nonprofit research institute that evaluates the cost effectiveness of pharmaceuticals, said Novartis’ price is within the upper bound of the organization’s value-based price benchmark range.

Briefs include:

  • A broad bipartisan draft health care legislation package containing dozens of provisions was recently released by the Senate Health Committee.
  • Forcing oncology practices to take on downside risk in CMS’ Oncology Care Model in July could result in more than half of them owing the government.
  • UnitedHealth Group pointed to price variations for diagnostic tests as a potential way to reduce overspending.
  • Mallinckrodt plans to spin off its specialty generics business to shareholders.
  • The FDA’s recent approval of Novartis’ Piqray (alpelisib).
  • FDA clears a new wearable device to treat migraine.
  • Biogen is scrapping its investigational treatment for Alzheimer’s disease, and is canceling its Phase III ENGAGE and EMERGE clinical trials.

About Darwin Research Group
Darwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.

CONNECT WITH US:

🌐 Visit us on the web

🌐 Follow Health Care Rounds on LinkedIn

🌐 Follow Darwin Research Group on LinkedIn

📺 Watch Health Care Rounds on YouTube

🎧 Listen on Apple Podcasts

🎧 Listen on Spotify

⚙️ Health Care Rounds is produced by Grippi Media

Recommended Next

Podcast 205: Why Health Care Treats Instead of Prevents w/ Dr. Barry R. Davis, Author, The Preventioneers
Podcast 204: What’s Really Holding Back Value-Based Care? w/ David Snow, Chairman & CEO, Cedar Gate Technologies
Podcast 203: Rebuilding Pediatric Care From the Ground Up w/ Danish Qureshi, Founder & CEO, Zarminali Pediatrics
Podcast 202: Lessons From Leading a Safety Net Hospital w/ Tesa Anewishki, President & CEO, Loretto Hospital
Podcast 201: How the VA Proved The Pharma Model Wrong w/ Dr. Eric Scott, U.S. Dept. of Veteran Affairs
Podcast 200: How Health Systems Build Elite Clinical Leaders w/ Dr. Jonathan Stallkamp, CMO, Main Line Health
Podcast 199: A New Blueprint for Rural Health Care w/ Natalie L. Baggio, President, Corewell Health South
Podcast 198: Standing Strong as an Independent Health System w/ Dr. Allen Smith & Dr. Sam Ash, South Shore Health

Recommended Content

Browse Library
INsights
May 11, 2026

Darwin's Our Take 5.11.26: UPMC to acquire Trinity Health from CommonSpirit, WakeMed to merge with Advocate’s Atrium Health

Read More
INsights
May 4, 2026

Darwin's Our Take: Regeneron’s ‘groundbreaking’ Otarmeni gains FDA approval

Read More
INsights
April 27, 2026

Darwin's Our Take: OpenAI unveils GPT-Rosalind to support life sciences research

Read More
Stay Aware. Stay Informed.

Subscribe to Our Take

Sign up for Our Take Newsletter: highly curated, expert weekly strategic insights for health care executives.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.